CLNN RSI Chart
Last 7 days
-5.1%
Last 30 days
8.8%
Last 90 days
-19.6%
Trailing 12 Months
-59.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 620.0K | 0 | 0 | 0 |
2023 | 550.0K | 784.0K | 718.0K | 654.0K |
2022 | 540.0K | 374.0K | 438.0K | 473.0K |
2021 | 349.0K | 541.0K | 553.0K | 723.0K |
2020 | 0 | 0 | 0 | 206.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 01, 2024 | general resonance llc | sold | -5,148 | 0.396 | -13,000 | - |
Apr 30, 2024 | general resonance llc | sold | -5,415 | 0.4166 | -13,000 | - |
Apr 24, 2024 | general resonance llc | sold | -3,278 | 0.3278 | -10,000 | - |
Apr 09, 2024 | general resonance llc | sold | -8,674 | 0.385533 | -22,500 | - |
Nov 10, 2023 | matlin david j | bought | 102,501 | 0.41 | 250,002 | - |
Jun 26, 2023 | etherington robert dee | bought | 20,250 | 0.81 | 25,000 | chief executive officer |
Jun 26, 2023 | stevens john henry | bought | 253,164 | 0.8 | 316,455 | - |
Jun 16, 2023 | mosca alison | bought | 1,915,500 | 0.8 | 2,394,380 | - |
Jun 16, 2023 | gay jonathon | bought | 84,500 | 0.8 | 105,625 | - |
Which funds bought or sold CLNN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -6,656 | - | -% |
May 16, 2024 | AWM Investment Company, Inc. | sold off | -100 | -798,214 | - | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -63.13 | -7,680 | 8,620 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 16,493 | 54,471 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | 43,616 | 144,055 | -% |
May 15, 2024 | Laird Norton Wetherby Trust Company, LLC | unchanged | - | 34,593 | 114,254 | 0.01% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 51.05 | 7,402 | 13,735 | -% |
May 15, 2024 | ADAR1 Capital Management, LLC | sold off | -100 | -3,411 | - | -% |
May 15, 2024 | AE Wealth Management LLC | sold off | -100 | -91,078 | - | -% |
May 15, 2024 | Alyeska Investment Group, L.P. | reduced | -71.89 | -298,637 | 201,695 | -% |
Unveiling Clene Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Clene Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Clene Inc. News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Revenue | -57.1% | 73,000 | 170,000 | 108,000 | 269,000 | 107,000 | 234,000 | 174,000 | 35,000 | 30,000 | 199,000 | 110,000 | 201,000 | 213,000 | 29,000 | 98,000 | 9,000 | 70,000 |
Cost Of Revenue | -57.9% | 16,000 | 38,000 | 12,000 | 66,000 | 5,000 | 7,000 | 19,000 | - | - | - | - | - | - | - | - | - | - |
Costs and Expenses | -7.9% | 9,305,000 | 10,100,000 | 9,650,000 | 10,605,000 | 10,839,000 | 11,907,000 | 9,979,000 | 13,630,000 | 13,366,000 | - | - | - | - | - | - | - | - |
Operating Expenses | - | - | - | - | - | - | - | 9,979,000 | 13,630,000 | 13,366,000 | 14,257,000 | 10,560,000 | 13,976,000 | 11,908,000 | 5,989,000 | 5,789,000 | 4,570,000 | 4,072,000 |
S&GA Expenses | -100.0% | - | 3,389,000 | 3,666,000 | 3,924,000 | 3,439,000 | 4,129,000 | 3,557,000 | 4,464,000 | 4,786,000 | 5,257,000 | 4,400,000 | 6,949,000 | 5,390,000 | 1,528,000 | 1,795,000 | 1,016,000 | 812,000 |
R&D Expenses | -12.0% | 5,869,000 | 6,673,000 | 5,972,000 | 6,615,000 | 7,395,000 | 7,771,000 | 6,403,000 | 9,166,000 | 8,580,000 | 9,523,000 | 6,146,000 | 6,472,000 | 6,275,000 | 4,454,000 | 3,994,000 | 3,554,000 | 3,202,000 |
EBITDA Margin | -3.4% | -68.34 | -66.12 | -48.10 | -55.65 | -42.78 | -54.13 | -50.87 | 44.91 | 31.76 | -13.15 | -20.40 | -93.25 | - | - | - | - | - |
Interest Expenses | 3.7% | 1,244,000 | 1,200,000 | 1,188,000 | 1,104,000 | 1,066,000 | 906,000 | 857,000 | 751,000 | 782,000 | -950,000 | 80,000 | 26,000 | 551,000 | - | - | 190,000 | 51,000 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | -215,000 | -69,000 | -72,000 | -72,000 | - | - | - | - |
Earnings Before Taxes | -8.9% | -11,080,000 | -10,173,000 | -2,418,000 | -25,143,000 | -11,770,000 | -1,054,000 | -10,976,000 | -4,534,000 | -13,354,000 | 4,208,000 | 28,875,000 | -3,423,000 | -39,828,000 | 1,184,000 | -10,295,000 | -5,819,000 | -3,941,000 |
EBT Margin | -4.0% | -78.73 | -75.69 | -56.25 | -62.43 | -51.52 | -63.25 | -56.29 | 40.63 | 30.20 | -14.06 | -23.86 | -96.79 | - | - | - | - | - |
Net Income | -8.9% | -11,080,000 | -10,173,000 | -2,418,000 | -25,143,000 | -11,770,000 | -1,054,000 | -10,976,000 | -4,534,000 | -13,354,000 | 4,423,000 | 28,944,000 | -3,351,000 | -39,756,000 | 778,000 | -10,295,000 | -5,819,000 | -3,941,000 |
Net Income Margin | -4.0% | -78.73 | -75.69 | -56.25 | -62.43 | -51.52 | -63.25 | -55.80 | 41.39 | 30.86 | -13.47 | -24.20 | -97.27 | - | - | - | - | - |
Free Cashflow | 1.7% | -7,093,000 | -7,215,000 | -6,847,000 | -6,961,000 | -9,478,000 | -9,412,000 | -10,140,000 | -10,618,000 | -14,020,000 | -10,253,000 | -7,559,000 | -8,717,000 | - | - | - | - | - |
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | -13.9% | 45.00 | 52.00 | 60.00 | 68.00 | 40.00 | 44.00 | 36.00 | 45.00 | 53.00 | 63.00 | 73.00 | 73.00 | 59.00 | 68.00 | 15.00 |
Current Assets | -17.4% | 32.00 | 39.00 | 46.00 | 53.00 | 25.00 | 29.00 | 21.00 | 32.00 | 42.00 | 55.00 | 65.00 | 68.00 | 53.00 | 63.00 | 9.00 |
Cash Equivalents | -24.4% | 22.00 | 29.00 | 42.00 | 49.00 | 18.00 | 18.00 | 7.00 | 7.00 | 13.00 | 50.00 | 61.00 | 63.00 | 48.00 | 59.00 | 9.00 |
Inventory | 0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net PPE | - | - | - | - | - | - | - | 10.00 | 8.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
Liabilities | 4.8% | 41.00 | 39.00 | 39.00 | 46.00 | 42.00 | 41.00 | 45.00 | 45.00 | 51.00 | 50.00 | 67.00 | 99.00 | 95.00 | 68.00 | 10.00 |
Current Liabilities | 3.4% | 26.00 | 25.00 | 15.00 | 6.00 | 17.00 | 14.00 | 6.00 | 8.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 12.00 | 4.00 |
LT Debt, Current | 3.4% | 5.00 | 5.00 | - | - | - | - | - | - | - | - | - | - | - | 6.00 | - |
Shareholder's Equity | -68.2% | 4.00 | 13.00 | 21.00 | 22.00 | -1.63 | 3.00 | - | - | 2.00 | 13.00 | 6.00 | - | - | 0.00 | - |
Retained Earnings | -4.6% | -253 | -242 | -232 | -230 | -205 | -193 | -192 | -181 | -176 | -163 | -167 | -196 | -193 | -153 | -69.57 |
Additional Paid-In Capital | 0.8% | 258 | 256 | 254 | 251 | 203 | 196 | 183 | 181 | 178 | 176 | 173 | 170 | 157 | 154 | 2.00 |
Shares Outstanding | 0.0% | 128 | 128 | 128 | 128 | 78.00 | 75.00 | 64.00 | 63.00 | 63.00 | 62.00 | 62.00 | 61.00 | - | - | - |
Float | - | - | - | - | 78.00 | - | - | - | 85.00 | - | - | - | 360 | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | 1.3% | -7,082 | -7,172 | -6,799 | -7,000 | -9,200 | -7,711 | -8,486 | -9,730 | -13,084 | -9,582 | -7,318 | -8,500 | -9,200 | -5,800 | -7,698 | -2,151 | -3,251 | - |
Share Based Compensation | -1.7% | 2,013 | 2,047 | 2,396 | 2,451 | 2,223 | 2,029 | 2,098 | 2,184 | 2,202 | 2,439 | 2,425 | 4,255 | 3,265 | 207 | 209 | 174 | 171 | - |
Cashflow From Investing | 101.1% | 71.00 | -6,212 | -48.00 | 39.00 | 4,722 | 2,282 | 8,411 | 3,665 | -24,522 | -671 | -241 | -217 | -203 | -118 | -75.00 | -171 | -23.00 | - |
Cashflow From Financing | -5.6% | -19.00 | -18.00 | -237 | 37,830 | 4,588 | 16,374 | 92.00 | 548 | 235 | -18.00 | 5,232 | 23,794 | -1,896 | 28,170 | 37,696 | 2,121 | 1,547 | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue: | ||
Total revenue | $ 73 | $ 107 |
Operating expenses: | ||
Cost of revenue | 16 | 5 |
Research and development | 5,869 | 7,395 |
General and administrative | 3,420 | 3,439 |
Total operating expenses | 9,305 | 10,839 |
Loss from operations | (9,232) | (10,732) |
Other income (expense), net: | ||
Interest income | 359 | 172 |
Interest expense | (1,244) | (1,066) |
Commitment share expense | 0 | (399) |
Change in fair value of common stock warrant liabilities | (1,309) | 0 |
Change in fair value of Clene Nanomedicine contingent earn-out liability | 53 | (55) |
Change in fair value of Initial Stockholders contingent earn-out liability | 7 | (7) |
Research and development tax credits and unrestricted grants | 286 | 314 |
Other income, net | 0 | 3 |
Total other income (expense), net | (1,848) | (1,038) |
Net loss before income taxes | (11,080) | (11,770) |
Income tax benefit | 0 | 0 |
Net loss | (11,080) | (11,770) |
Other comprehensive income (loss): | ||
Unrealized gain (loss) on available-for-sale securities | (4) | 14 |
Foreign currency translation adjustments | (55) | 4 |
Total other comprehensive income (loss) | (59) | 18 |
Comprehensive loss | $ (11,139) | $ (11,752) |
Net loss per share – basic and diluted (in dollars per share) | $ (0.09) | $ (0.15) |
Weighted average common shares used to compute basic and diluted net loss per share (in shares) | 128,427,231 | 76,049,665 |
Product [Member] | ||
Revenue: | ||
Total revenue | $ 44 | $ 64 |
Royalty [Member] | ||
Revenue: | ||
Total revenue | $ 29 | $ 43 |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 21,732 | $ 28,821 |
Marketable securities | 6,178 | 6,179 |
Accounts receivable | 64 | 143 |
Inventory | 37 | 37 |
Prepaid expenses and other current assets | 4,100 | 3,672 |
Total current assets | 32,111 | 38,852 |
Restricted cash | 58 | 58 |
Operating lease right-of-use assets | 4,046 | 4,168 |
Property and equipment, net | 8,854 | 9,263 |
TOTAL ASSETS | 45,069 | 52,341 |
Current liabilities: | ||
Accounts payable | 1,645 | 1,504 |
Accrued liabilities | 3,905 | 3,720 |
Operating lease obligations, current portion | 599 | 576 |
Finance lease obligations, current portion | 7 | 27 |
Notes payable, current portion | 14,987 | 14,627 |
Convertible notes payable, current portion | 5,042 | 4,876 |
Total current liabilities | 26,185 | 25,330 |
Operating lease obligations, net of current portion | 4,720 | 4,903 |
Notes payable, net of current portion | 1,820 | 1,894 |
Convertible notes payable, net of current portion | 5,265 | 5,258 |
Common stock warrant liabilities | 2,790 | 1,481 |
Clene Nanomedicine contingent earn-out liability | 22 | 75 |
Initial Stockholders contingent earn-out liability | 3 | 10 |
TOTAL LIABILITIES | 40,805 | 38,951 |
Commitments and contingencies (Note 9) | ||
Stockholders’ equity: | ||
Common stock, $0.0001 par value: 300,000,000 and 300,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 128,433,721 and 128,422,851 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 13 | 13 |
Additional paid-in capital | 257,914 | 255,901 |
Accumulated deficit | (253,803) | (242,723) |
Accumulated other comprehensive income | 140 | 199 |
TOTAL STOCKHOLDERS’ EQUITY | 4,264 | 13,390 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 45,069 | $ 52,341 |